Abstract
Genetics has been integrated into patient care across many subspecialties. However, genetic and genomic testing (GT) remain expensive with disparities in access both within Canada and internationally. It is, therefore, not surprising that sponsored GT has emerged as one alternative. Sponsored GT, for the purpose of this document, refers to clinical-grade GT partially or fully subsidised by industry. In return, industry sponsors—usually pharmaceutical or biotechnology companies—may have access to patients’ genetic data, practitioner information, DNA and/or other information. The availability of sponsored GT options in the Canadian healthcare landscape has appeared to simplify patient and practitioner access to GT, but the potential ethical and legal considerations, as well as the nuances of a publicly funded healthcare system, must also be considered. This document offers preliminary guidance for Canadian healthcare practitioners encountering sponsored GT in practice. Further research and dialogue is urgently needed to explore this issue to provide fulsome considerations that one must be aware of when availing such options.
Subject
Genetics (clinical),Genetics
Reference26 articles.
1. Laboratory business models and practices: implications for availability and access to Germline genetic testing;Scheuner;Genet Med,2021
2. Beauchamp T , Childress J . Principles of Biomedical Ethics, 8th ed. Oxford University Press, 2019.
3. Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked Hypophosphatemia (XLH);Sarafrazi;Hum Mutat,2022
4. Molecular diagnoses of X-linked and other genetic hypophosphatemias: results from a sponsored genetic testing program;Rush;J Bone Miner Res,2022
5. Bowen BM , Truty R , Aradhya S , et al . SMA identified: clinical and molecular findings from a sponsored testing program for spinal muscular atrophy in more than 2,000 individuals. Front Neurol 2021;12:663911. doi:10.3389/fneur.2021.663911